lrn.peerview.com Open in urlscan Pro
2606:4700::6812:1449  Public Scan

Form analysis
0 forms found in the DOM

Text Content

THIS CONTENT WAS DESIGNED FOR
PORTRAIT ORIENTATION ONLY.



CME/MOC/NCPD/ILNA/IPCE Information Practice AidsSlidesPodcastsAbbr.ShareFeedback
1.5 CME/MOC/NCPD/ILNA/IPCEThis activity expired on May 25, 2025; credit is no
longer available.
Ten Steps for Highly Successful Myeloma Care: Guidance on the Road to Remission
With Antibodies, BCMA Immunotherapy, and Other Innovations


Please complete and tap Submit at the end to continue.

Question 1/5
Which statement is true regarding the efficacy of isatuximab quadruplets (ie,
adding isatuximab to carfilzomib or bortezomib-based platforms)?
 * Adding isatuximab was active but did not produce MRD-negative responses
   
   
 * Adding isatuximab did not improve activity compared with triplets
   
   
 * Adding isatuximab was active and produced MRD-negative responses
   
   
 * Isatuximab was active when combined with carfilzomib but not bortezomib
   platforms
   
   
 * I’m not sure
   
   
   

Question 2/5
You are managing an older patient with RRMM who is preparing for therapy with
the bispecific antibody teclistamab. Assuming that you have counseled the
patient on dosing for the step-up period, how would you proceed when educating
the patient on subsequent dosing aspects?
 * Note a 1.5 mg/kg weekly dose and the potential of every 2-week dosing based
   on response
   
   
 * Note a 0.3 mg/kg weekly dose and the potential of every 2-week dosing based
   on response
   
   
 * Educate the patient on continuous, 1.5 mg/kg weekly dosing
   
   
 * Note a 0.06 mg/kg weekly dose and use of every 2-week dosing based on
   response
   
   
 * I’m not sure
   
   
   

Question 3/5
Think of a future scenario where you are managing a patient with RRMM on
treatment with the novel BCMA x CD3 antibody linvoseltamab, first at the 200 mg
IV weekly then biweekly schedule. If the patient achieves ≥VGPR after week 24,
how would you address dosing considerations going forward?
 * Plan for a dose of 100 mg every 4 weeks
   
   
 * Suggest staying on the dose of 200 mg every 2 weeks
   
   
 * Plan for a dose of 200 mg every 4 weeks
   
   
 * Suggest reverting to a dose of 200 mg every week
   
   
 * I’m not sure
   
   
   

Question 4/5
Consider a fit adult patient with RRMM and a PS of 1 with early progression
after lenalidomide maintenance with VRd induction prior to ASCT. Assuming this
patient is willing to pursue aggressive treatment, how would you plan for the
next steps in care while working with your colleagues on the healthcare team?
 * Plan for CAR-T with no bridging
   
   
 * Plan for treatment with a CD38-based regimen (no CAR-T)
   
   
 * Plan for the use of an alternative lenalidomide-based treatment
   
   
 * Plan for CAR-T, bridge with Dara-Pd, then refer to CAR-T
   
   
 * I’m not sure
   
   
   

Question 5/5
Assume that you are developing a safety care plan for a patient with NDMM
preparing to receive a CD38 antibody platform. How would you plan to mitigate
hypersensitivity reactions?
 * Plan for steroid premedication prior to therapy
   
   
 * Plan for premedication with acetaminophen and diphenhydramine
   
   
 * Plan for premedication with acetaminophen, diphenhydramine, and steroids
   
   
 * Plan for optional premedication with acetaminophen, diphenhydramine, and
   steroids
   
   
 * I’m not sure
   
   
   

Submit
CHAIR & MODERATOR

Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO
Cleveland Clinic Taussig Cancer Institute
Department of Hematology and Medical Oncology
Member, Population and Cancer Prevention Program
Case Comprehensive Cancer Center
Cleveland, Ohio

PRESENTER

Donna D. Catamero, ANP-BC, OCN, CCRC
Associate Director, Myeloma Research
The Mount Sinai Health System
New York, New York

PRESENTER

Charise Gleason, MSN, NP-C, AOCNP
Vice President and Chief Advanced Practice Officer
Emory Healthcare
Atlanta, Georgia

In support of improving patient care, this activity has been planned and
implemented by PVI, PeerView Institute for Medical Education, and HealthTree
Foundation for Multiple Myeloma. PVI, PeerView Institute for Medical Education,
is jointly accredited by the Accreditation Council for Continuing Medical
Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and
the American Nurses Credentialing Center (ANCC), to provide continuing education
for the healthcare team.

Support

This activity is supported by educational grants from Bristol Myers Squibb,
Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC,
Regeneron Pharmaceuticals, Inc., and Sanofi.

Physicians

PVI, PeerView Institute for Medical Education, designates this enduring material
for a maximum of 1.5 AMA PRA Category 1 CreditsTM. Physicians should claim only
the credit commensurate with the extent of their participation in the activity.

MOC Statement

Successful completion of this CME activity, which includes participation in the
evaluation component, enables the participant to earn up to 1.5 MOC points and
patient safety MOC credit in the American Board of Internal Medicine’s (ABIM)
Maintenance of Certification (MOC) program. It is the CME activity provider’s
responsibility to submit participant completion information to ACCME for the
purpose of granting ABIM MOC credit.

Participation information will be shared through the ACCME’s Program and
Activity Reporting System (PARS).

Through an agreement between the Accreditation Council for Continuing Medical
Education and the Royal College of Physicians and Surgeons of Canada, medical
practitioners participating in the Royal College MOC Program may record
completion of accredited activities registered under the ACCME’s “CME in Support
of MOC” program in Section 3 of the Royal College’s MOC Program.

Nurses

Successful completion of this nursing continuing professional education activity
will be awarded 1.5 contact hour(s) and 1.50 contact hour(s) in the area of
pharmacology.

ILNA Coding Statement

The program content has been reviewed by the Oncology Nursing Certification
Corporation (ONCC) and is acceptable for recertification points as follows:
1.5 points: Care Continuum, Nursing Practice, Professional Practice/Performance,
Psychosocial Dimension of Care, Roles of the APRN, Symptom Management,
Palliative Care, Supportive Care, Treatment

The numerical value(s) indicated above is the maximum amount of points that can
be claimed in each subject area domain. The total amount of points claimed may
not exceed the total amount of nursing continuing professional development
(NCPD) or CME awarded from this course and may only apply to the credential
being renewed.

Interprofessional Continuing Education (IPCE) Statement

This activity was planned by and for the healthcare team, and learners will
receive 1.5 Interprofessional Continuing Education (IPCE) credits for learning
and change.

Disclosure Policy

PVI, PeerView Institute for Medical Education, disclosure policy adheres to The
Standards for Integrity and Independence in Accredited Continuing Education. All
individuals in a position to control the content of a CE activity, including
faculty, planners and reviewers are required to disclose all financial
relationships with ineligible companies (commercial interests) that as an entity
produces, markets, re-sells or distributes healthcare goods or services consumed
by or used on patients. All relevant conflicts of interest have been mitigated
prior to the commencement of the activity.

Faculty/Planner Disclosures

Chair/Planner
Beth Faiman, PhD, MSN, APN-BC, AOCN, BMTCN, FAAN, FAPO, has a financial
interest/relationship or affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; GlaxoSmithKline; Janssen
Pharmaceuticals, Inc.; Karyopharm Therapeutics; Pfizer; and Sanofi.


Faculty/Planner
Donna D. Catamero, ANP-BC, OCN, CCRC, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Bristol Myers Squibb; Janssen Pharmaceuticals,
Inc.; Karyopharm Therapeutics; and Pfizer.
Speaker for Bristol Myers Squibb and Janssen Pharmaceuticals, Inc.


Faculty/Planner
Charise Gleason, MSN, NP-C, AOCNP, has a financial interest/relationship or
affiliation in the form of:
Consultant and/or Advisor for Pfizer.


Planning Committee and Reviewer Disclosures

Planners, independent reviewers, and staff of PVI, PeerView Institute for
Medical Education, do not have any relevant financial relationships related to
this CE activity unless listed below.

CONNECT WITH US



Copyright © 2000-2024, PeerView
Terms of Use | Privacy Policy | Sign Up for Email Alerts


This site uses cookies.Learn More.
×